Wolpin, B. M., Wainberg, Z. A., Hendifar, A., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., O'Reilly, E. M. (2026). Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba5